Healthcare

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated...

Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids

– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative...

Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China’s Growing $29 Billion Aesthetic Medicine Market

Partnership is with HTDK Group, wholly owned by Warburg PincusHTDK Group is a leading healthcare solutions provider which sells into...

Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-10, 2022

error: Content is protected !!